TABLE 4.
Use of MHT after diagnosis and ovarian cancer‐specific survival among women ≤55 years at diagnosis (n = 259).
| All (n = 259) | HGSC (n = 143) | LGSC & END (n = 59) | Other histotypes (n = 57) | |||
|---|---|---|---|---|---|---|
| MHT use | Total (n, %) | Deaths (n, %) | HR (95%CI) | HR (95%CI) | HR (95%CI) | HR (95%CI) |
| MHT use time‐varying | ||||||
| No | NA b | NA b | 1.0 | 1.0 | 1.0 | 1.0 |
| Yes | NA b | NA b | 0.73 (0.41–1.31) | 0.92 (0.46–1.83) | 1.28 (0.22–7.27) | 0.04 (0.004–0.30) |
| MHT use a | ||||||
| No | 214 (83) | 85 (86) | 1.0 | 1.0 | 1.0 | 1.0 |
| Yes | 45 (17) | 14 (14) | 0.89 (0.49–1.62) | 1.04 (0.51–2.14) | 1.29 (0.18–8.98) | 0.11 (0.01–1.14) |
| MHT changea | ||||||
| Never | 200 (77) | 81 (82) | 1.0 | 1.0 | 1.0 | 1.0 |
| Use prior to diagnosis only | 14 (5) | 4 (4) | 0.64 (0.22–1.84) | 0.31 (0.07–1.33) | NA | 1.40 (0.15–13.5) |
| Continuous use | 8 (3) | 4 (4) | 0.76 (0.27–2.12) | 0.71 (0.25–2.01) | NA | NA |
| New use | 37 (14) | 10 (10) | 0.84 (0.43–1.64) | 0.84 (0.35–2.01) | 1.44 (0.21–9.78) | 0.11 (0.01–1.16) |
Note: Models adjusted for age (continuous), body mass index (<25, 25–29, 30+ kg/m2), smoking (never, former, current), FIGO Stage (I & II, III & IV), residual disease (none, any) and further adjusted for pre‐diagnosis MHT use (yes, no) except for the analysis of MHT change.
Abbreviations: CI, confidence interval; HR, hazard ratio; MHT: menopausal hormone therapy.
a
MHT use during the first year after diagnosis.
b
Time‐varying.
c
The models did not converge due to an insufficient number of samples.